The benefit of GLP-1R agonists for reducing chronic hyperinsulinemia might be one mechanism that explains the inhibitory effects on cancer risk in clinical studies and on cancer progression in preclinical settings. The gene discussed is GLP1R; the disease is Hyperinsulinemia.